5alpha-reductase: History and Clinical Importance

Overview

Journal Rev Urol

Date 2006 Sep 21

PMID 16985920

Citations 28

Authors

Leonard S Marks

Affiliations

Soon will be listed here.

Abstract

The treatment of men with symptomatic benign prostatic hyperplasia (BPH) has shifted dramatically from surgery to drug therapy over the past decade. The revolution in BPH treatment began with the discovery of congenital 5alpha-reductase (5AR) deficiency, leading to the appreciation of 2 different androgenic hormones: testosterone, which mediates overt masculinization in the adult male, and dihydrotestosterone (DHT), which mediates prostatic growth, acne, facial beard, and male pattern baldness. Inhibition of DHT in adults results in prostatic shrinkage and symptomatic relief in many men, without the side effects seen with conventional androgen-deprivation therapy. The 5AR inhibitor drugs (finasteride and the dual inhibitor, dutasteride) are able to ablate the accumulation of intraprostatic DHT, the mechanism most responsible for prostate growth and maintenance. Not only may these drugs relieve symptoms, but they may also alter the natural history of the BPH process. Future indications for the 5ARI drugs could include chemoprevention of prostate cancer, prophylaxis of BPH-related complications, and treatment of BPH-associated hematuria.

Citing Articles

Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms.

Hassan M, Flanagan T, Eshaq A, Altamimi O, Altalag H, Alsharif M Cancers (Basel). 2025; 17(5).

PMID: 40075690 PMC: 11898507. DOI: 10.3390/cancers17050843.

Abuse of Anabolic-Androgenic Steroids as a Social Phenomenon and Medical Problem-Its Potential Negative Impact on Reproductive Health Based on 50 Years of Case Report Analysis.

Skrzypiec-Spring M, Rozmus J, Abu Faraj G, Brawanska-Masluch K, Kujawa K, Szelag A J Clin Med. 2024; 13(19).

PMID: 39407952 PMC: 11478083. DOI: 10.3390/jcm13195892.

The effect of testosterone on the gut microbiome in mice.

Moadi L, Turjeman S, Asulin N, Koren O Commun Biol. 2024; 7(1):880.

PMID: 39030253 PMC: 11271554. DOI: 10.1038/s42003-024-06470-5.

Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese.

Hung S, Chang L, Hsiao T, Lin G, Wang S, Li J Hum Genomics. 2024; 18(1):49.

PMID: 38778357 PMC: 11110300. DOI: 10.1186/s40246-024-00619-3.

A clinical guide to rare male sexual disorders.

Gul M, Fode M, Urkmez A, Capogrosso P, Falcone M, Sarikaya S Nat Rev Urol. 2023; 21(1):35-49.

PMID: 37670085 DOI: 10.1038/s41585-023-00803-5.

References

Andriole G, Roehrborn C, Schulman C, Slawin K, Somerville M, Rittmaster R . Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004; 64(3):537-41. DOI: 10.1016/j.urology.2004.04.084. View

Rittmaster R, Stoner E, Thompson D, Nance D, Lasseter K . Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl. 1989; 10(4):259-62. DOI: 10.1002/j.1939-4640.1989.tb00097.x. View

Brooks J, Berman D, Glitzer M, Gordon L, Primka R, Reynolds G . Effect of a new 5 alpha-reductase inhibitor on size, histologic characteristics, and androgen concentrations of the canine prostate. Prostate. 1982; 3(1):35-44. DOI: 10.1002/pros.2990030107. View

Walsh P, Madden J, Harrod M, Goldstein J, MACDONALD P, Wilson J . Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974; 291(18):944-9. DOI: 10.1056/NEJM197410312911806. View

Roehrborn C, Marks L, Fenter T, Freedman S, Tuttle J, Gittleman M . Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004; 63(4):709-15. DOI: 10.1016/j.urology.2004.01.001. View

Oesterling J, Epstein J, Walsh P . The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol. 1986; 136(5):1030-4. DOI: 10.1016/s0022-5347(17)45198-6. View

Huggins C, Hodges C . Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972; 22(4):232-40. DOI: 10.3322/canjclin.22.4.232. View

McConnell J . Prostatic growth: new insights into hormonal regulation. Br J Urol. 1995; 76 Suppl 1:5-10. View

Peterson R, Imperato-McGinley J, Gautier T, Sturla E . Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Am J Med. 1977; 62(2):170-91. DOI: 10.1016/0002-9343(77)90313-8. View

10.

McConnell J, Roehrborn C, Bautista O, Andriole Jr G, Dixon C, Kusek J . The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349(25):2387-98. DOI: 10.1056/NEJMoa030656. View

11.

Roehrborn C, Boyle P, Nickel J, Hoefner K, Andriole G . Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002; 60(3):434-41. DOI: 10.1016/s0090-4295(02)01905-2. View

12.

Lazier C, Thomas L, Douglas R, Vessey J, Rittmaster R . Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate. 2004; 58(2):130-44. DOI: 10.1002/pros.10340. View

13.

Jacobsen S, Girman C, Lieber M . Natural history of benign prostatic hyperplasia. Urology. 2001; 58(6 Suppl 1):5-16; discussion 16. DOI: 10.1016/s0090-4295(01)01298-5. View

14.

Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E . Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab. 1992; 75(4):1022-6. DOI: 10.1210/jcem.75.4.1400866. View

15.

Bostwick D, Qian J, Civantos F, Roehrborn C, Montironi R . Does finasteride alter the pathology of the prostate and cancer grading?. Clin Prostate Cancer. 2004; 2(4):228-35. DOI: 10.3816/cgc.2004.n.004. View

16.

Thomas L, Douglas R, Vessey J, Gupta R, Fontaine D, Norman R . 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol. 2003; 170(5):2019-25. DOI: 10.1097/01.ju.0000091804.20183.81. View

17.

Wu C, Gu F . The prostate in eunuchs. Prog Clin Biol Res. 1991; 370:249-55. View

18.

Gisleskog P, Hermann D, Hammarlund-Udenaes M, Karlsson M . A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther. 1999; 64(6):636-47. DOI: 10.1016/S0009-9236(98)90054-6. View

19.

Bartsch G, Rittmaster R, Klocker H . Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002; 19(6):413-25. DOI: 10.1007/s00345-002-0248-5. View

20.

Iehle C, Radvanyi F, Gil Diez de Medina S, Ouafik L, Gerard H, Chopin D . Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol. 1999; 68(5-6):189-95. DOI: 10.1016/s0960-0760(99)00030-8. View